New findings from HELIOS-B Phase 3 trial show reduced rates of gastrointestinal symptoms

Alnylam Pharmaceuticals Inc. announced that they would be participating in the 39th Annual J.P. Morgan Healthcare Conference. The company intends to provide an update on its recent progress and discuss its future plans at this prestigious event. Alnylam’s presentation is scheduled for January 8, 2021, at 10:50 a.m. ET.

Alnylam is a biopharmaceutical company that focuses on developing RNA interference (RNAi) therapeutics. The company’s pipeline includes investigational RNAi therapeutics for the treatment of a variety of diseases. Alnylam is dedicated to advancing innovative therapies that have the potential to make a meaningful difference in patients’ lives.

During the presentation, Alnylam plans to provide an overview of its recent achievements, including regulatory approvals and advancements in its research and development programs. The company will also discuss its strategic priorities for the future and its commitment to delivering transformative therapies to patients in need.

Alnylam’s participation in the J.P. Morgan Healthcare Conference demonstrates its ongoing engagement with the healthcare and investment communities. The conference provides a platform for companies to showcase their progress and engage with key stakeholders in the industry. By participating in this conference, Alnylam has the opportunity to highlight its innovative approach to drug development and showcase its potential for future growth.

Investors and stakeholders will be able to access Alnylam’s presentation through a live webcast on the company’s website. The presentation will also be available for replay following the event. This accessibility ensures that interested parties can stay informed about Alnylam’s latest developments and strategic initiatives.

In conclusion, Alnylam Pharmaceuticals Inc. will be participating in the 39th Annual J.P. Morgan Healthcare Conference to provide an update on its progress and discuss its future plans. The company remains committed to developing innovative RNAi therapeutics for the treatment of various diseases and aims to make a significant impact on patients’ lives. By engaging with the healthcare and investment communities through events like this conference, Alnylam demonstrates its dedication to transparency and collaboration. Interested parties can access the presentation through a live webcast on the company’s website and stay informed about Alnylam’s advancements in the field of RNAi therapeutics.